Similar with what Sakre N et al reported, we detected RICTOR amplification in 5.7% (7/122) of SCLC patients who might respond to mTORC1/2 inhibitors.20 Besides, we found FGFR1 amplifications in 4.9% (6/122) of SCLC patients, and FGFR inhibitors are currently being tested in such patients.21 Although the mutation events of these targetable genes are not very common, due to the fact that lung cancers are very prevalent and numerous, even small subgroups represent a large number of patients in need of therapy in China and worldwide.22 This evidence concerns the gene FGFR1 and lung carcinoma.